Sellas Life Sciences Group Inc Earnings

The next earnings date for Sellas Life Sciences Group Inc is March 13, 2026.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Sellas Life Sciences Group Inc Earnings

Report Date	Estimated Earnings Per Share
03/13/2026	$-0.08

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Sellas Life Sciences Group Inc Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
11/12/2025	---	$0	100.00%
08/07/2025	---	$0	100.00%
05/12/2025	Before Market	$-0.07	66.67%
03/26/2025	Before Market	$-0.08	25.02%
11/07/2024	Before Market	$-0.10	21.07%
08/13/2024	After Market	$-0.13	18.75%
05/14/2024	After Market	$-0.21	-31.25%
03/28/2024	After Market	$-0.25	-377.78%
11/09/2023	After Market	$-0.33	-1,200.00%
08/10/2023	After Market	$-0.31	11.43%
05/11/2023	After Market	$-0.47	-62.07%
03/16/2023	After Market	$-0.43	-34.38%
11/14/2022	Before Market	$-0.34	12.82%
08/11/2022	After Market	$-0.41	-17.14%
05/12/2022	After Market	$-1.05	-176.32%
03/31/2022	After Market	$-0.42	-2.44%
11/12/2021	Before Market	$-0.45	-18.42%
08/12/2021	After Market	$-0.30	23.08%
05/13/2021	After Market	$-0.16	40.74%
03/23/2021	After Market	$-0.28	0.00%
11/13/2020	After Market	$-0.53	-76.67%
08/13/2020	After Market	$-0.66	-3.13%
05/14/2020	After Market	$-0.66	10.81%
03/13/2020	Before Market	$-1.54	-113.89%
11/14/2019	After Market	$-2.68	-168.00%
08/14/2019	After Market	$-6.50	27.78%
05/15/2019	After Market	$-11	-7.32%
03/22/2019	Before Market	$-8.50	27.66%
11/14/2018	After Market	$-27.50	-42.86%
08/14/2018	After Market	$-63	-22.33%
04/13/2018	After Market	$-65	-22.64%
03/15/2018	---	$-49.50	-4,569.81%
11/09/2017	After Market	$-30	86.67%
08/14/2017	After Market	$-330	-22.22%
05/10/2017	After Market	$-675	-104.55%
03/15/2017	After Market	$-735	5.77%
11/09/2016	After Market	$-900	33.33%
08/09/2016	After Market	$1,200	164.00%
05/10/2016	After Market	$-2,700	-40.63%
03/10/2016	After Market	$-1,500	6.25%
11/09/2015	After Market	$-3,300	-60.42%
08/06/2015	After Market	$-3,000	-8.70%
05/07/2015	After Market	$-2,400	7.69%
03/05/2015	After Market	$-1,800	42.86%
11/03/2014	After Market	$-1,500	56.04%
08/11/2014	---	$-5,100	-88.89%
05/06/2014	---	$-600	70.91%
03/17/2014	---	$-13,800	-398.79%
11/06/2013	---	$-3,300	0.00%
08/08/2013	---	$-3,300	-6.02%
05/09/2013	---	$-3,300	-48.08%
03/12/2013	---	$-1,200	60.56%
11/13/2012	---	$-2,700	-5.88%
08/14/2012	---	$-210	95.63%
05/14/2012	---	$-15,600	-420.00%
03/28/2012	---	$1,200	126.67%
11/14/2011	---	$-3,900	18.75%
08/15/2011	---	$-1,200	42.86%
05/15/2011	---	$-5,672.40	---
11/15/2010	---	$-6,900	2.13%
08/11/2010	---	$-3,600	50.00%
05/17/2010	---	$-7,200	11.11%
03/31/2010	---	$-11,400	-52.00%
11/16/2009	---	$-5,846.95	---
08/14/2009	---	$-11,100	-23.33%
05/15/2009	---	$-9,000	-3.45%
03/18/2009	---	$-8,700	-462.50%
11/14/2008	---	$-7,500	21.88%
08/14/2008	---	$-10,200	-54.55%
05/20/2008	---	$-11,700	-21.88%

More About Sellas Life Sciences Group Inc

Website

https://www.sellaslifesciences.com

Country

USA

Full Time Employees

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

“Sellas Life Sciences Group Inc Earnings” Can Refer to the Sellas Life Sciences Group Inc Earnings Date

Some people say “Sellas Life Sciences Group Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Sellas Life Sciences Group Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Sellas Life Sciences Group Inc Stock on the Earnings Date

If you own Sellas Life Sciences Group Inc stock (SLS) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Sellas Life Sciences Group Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Sellas Life Sciences Group Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Sellas Life Sciences Group Inc Earnings

You can contact us any time if you would like to ask questions about Sellas Life Sciences Group Inc earnings or anything else related to the stock market.